Parmar, Katrin http://orcid.org/0000-0002-4251-6238
Fonov, Vladimir S.
Naegelin, Yvonne
Amann, Michael
Wuerfel, Jens
Collins, D. Louis
Gaetano, Laura
Magon, Stefano
Sprenger, Till
Kappos, Ludwig
Granziera, Cristina
Tsagkas, Charidimos
Funding for this research was provided by:
Universität Basel
Article History
Accepted: 21 July 2021
First Online: 21 August 2021
Change Date: 11 November 2021
Change Type: Update
Change Details: Funding note Open access funding provided by University of Basel is added.
Declarations
:
: All patients provided written informed consent and the study was approved by the local ethics committee (Ethikkommission beider Basel – 46/04). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
: K. Parmar: has no relevant financial or non-financial interests to disclose.V.S. Fonov: the author was formerly employed by Neuro RX Research Inc. and now employed by Rogue-Research Inc. NeuroRX is a contract research organization working with Acorda, Biogen, Celgene, Genentech, Roche, MedImmune, Mitsubishi Tanabe Pharma, Novartis, Receptos, and Sanofi. Nothing was related to this study.Y. Naegelin: her employer, the University Hospital Basel, received payments for lecturing from Celgene GmbH and Teva Pharma AG that were exclusively used for research support, not related to this study.M. Amann: has no relevant financial or non-financial interests to disclose.J. Wuerfel: CEO of MIAC AG, Basel, Switzerland; speaker honoraria (Bayer, Biogen, Novartis, Teva); advisory boards and research grants (Biogen, Idorsia, Novartis, Roche, Sanofi); he was or is supported by EU (Horizon2020), SNSF, German Ministry of Science (BMBF/KKNMS) and German Ministry of Economy (BMWi).D.L. Collin: the author received research funding from the Canadian National Science and Engineering Research Council and the Canadian Institutes of Health Research; co-founder of True-Positive Medical Devices; received compensation for consulting from NeuroRx Research. Nothing was related to this study.L. Gaetano: the author is an employee of F. Hoffmann-La Roche Ltd, Basel, Switzerland.S. Magon: the author is an employee of F. Hoffmann-La Roche Ltd, Basel, Switzerland.T. Sprenger: the current and previous employers of TS have received compensation for his serving on scientific advisory boards or speaking fees from Novartis, ATI, Electrocore, Sanofi Genzyme, Actelion, Jansen, Teva, Mitsubishi Pharma Europe and Biogen Idec.L. Kappos: author’s institution (University Hospital Basel) received in the last 3 years and used exclusively for research support at the Department: steering committee, advisory board and consultancy fees from Actelion, Almirall, Bayer, Biogen, Celgene/Receptos, Eisai, Genzyme, Japan Tobacco, Merck, Minoryx, Novartis, Roche, sanofi-aventis, Santhera, Teva and royalties for Neurostatus-UHB products. For educational activities, the institution received payments and honoraria from Allergan, Almirall, Baxalta, Bayer, Biogen, CSL-Behring, Desitin, Excemed, Genzyme, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Teva.C. Granziera: has no relevant financial or non-financial interests to disclose.Ch. Tsagkas: has no relevant financial or non-financial interests to disclose.